The effect of resveratrol on metabolism and cardiovascular risk profile in patients with chronic obstructive pulmonary disease (COPD) - CARMENS-trial

Medisch Universitair Ziekenhuis Maastricht0 个研究点目标入组 23 人开始时间: 待定最近更新: 2024年4月23日

适应症

试验速览

Trial ended prematurely

•- COPD patients planned for pulmonary rehabilitation or who recently participated in a rehabilitation program in the previous 6 months;
•- Investigator*s uncertainty about willingness or ability of the patient to comply with the protocol requirements;
•- Participation in any other study involving investigational exercise training, nutritional or pharmacological intervention;
•- Oral glucocorticoid use;
•- Recent exacerbation (<4 weeks) that required oral steroids and/or hospital admission;
•- Subject is pregnant, planning to be pregnant during the study period, lactating, or women who consider themselves to be of childbearing potential and who are engaged in an active sex life and are unwilling to commit to the use of an approved form of contraception throughout the study period. The method of contraception must be recorded in the source documentation;
•- Diabetes mellitus (type 1 and 2);
•- Active cardiovascular disease or a cardiovascular event (such as myocardial infarction, cerebrovascular haemorrhage/infarction) in the previous 6 months;
•- Recent major surgery;
•- Thyroid dysfunction, current hepatic or renal disorders;
•- Current malignancy (except for dermal malignancies);
•- Central or obstructive sleep apnea;
•- Current alcohol consumption > 20 grams alcohol/day;
•- Intake of resveratrol containing dietary supplements;

发起方

Medisch Universitair Ziekenhuis Maastricht